Regional Monitoring System for the Monitoring of the availability of Antimalarial Medications

Transcription

1 Strengthening Pharmaceutical Systems Regional Monitoring System for the Monitoring of the availability of Antimalarial Medications John Marmion Henrry Espinoza December 2011 Strengthening Pharmaceutical Systems Centro para la Gestión Farmacéutica Management Sciences for Health 4301 North Fairfax Drive, Suite 400 Arlington, VA USA Teléfono: Facsímil:

2 This report is made possible by the generous support of the American people through the U.S. Agency for International Development (USAID), under the terms of cooperative agreement number GHN-A The contents are the responsibility of Management Sciences for Health and do not necessarily reflect the views of USAID or the United States Government. About SPS The Strengthening Pharmaceutical Systems (SPS) Program strives to build capacity within developing countries to effectively manage all aspects of pharmaceutical systems and services. SPS focuses on improving governance in the pharmaceutical sector, strengthening pharmaceutical management systems and financing mechanisms, containing antimicrobial resistance, and enhancing access to and appropriate use of medicines. Summary Recently the Amazon Basin countries have experienced medication supply problems. Changing malaria incidence and distribution of medications have influenced the ability to program needs accurately. This report actsas a guide for the regional monitoring system for the availability of antimalarial medications. Citation This report can be reproduced with credit given to SPS. Please use the following citation. Marmion, John, Henrry Espinoza Dec Analysis of Antimalarial Medicine Availability in Amazon Basin Countries. Presented to the United States Agency for International Development through the Strengthening Pharmaceutical Systems (SPS) Program. Arlington, VA: Management Sciences for Health Key Words: Malaria, medication, availability, supply Strengthening Pharmaceutical Systems Center for Pharmaceutical Management Management Sciences for Health 4301 North Fairfax Drive, Suite 400 Arlington, VA USA Telephone: Fax: sps@msh.org Web: 2

3 Table of Contents... Error! Bookmark not defined. Procedure... 4 Introduction... 4 Description of the procedure for the collection and analysis of national and regional information... 4 Annex 1. Warehouse Report... 7 Annex 2: List of Antimalarial Medications... 9 Anex 3: Consolidated National Report Annex 4. Technical Report for the national Situation for Antimalarial Availability Ecuador, 2011 (Model) Annex 5: Consolidated Regional Report Annex 6: Quarterly Technical Report on the Regional Situation of Antimalarial Availability. 2 nd Quarter 2011 (Model)

4 Procedure Introduction The Amazon Malaria Iniciative (AMI) with financing from the United States Agency for International Development supports technical assistance activities to control malaria in countries that make up the Amazon basin. Due to the decrease of malaria incidence in the Region of the Americas some countries began to experience supply management problems around Overstocked situations were due to decreased while under stock were due to few manufacturers that were willing to produce quantities as small as the ones necessary for the incidence in the countries. MSH has collected data and indicators since 2009 on availability of antimalarials in the central warehouses and some regional warehouses in the hopes of monitoring the stock situation. The indicator used in the regional monitoring system is availability of medications in months. It is calculated by dividing the units of medication on-hand by the average monthly /distribution of each warehouse during the previous 12 months. The indicator can be used to determine months of stock on hand at each warehouse individually. For past reports, data was presented and discussed with malaria program directors and technical staff responsible for medication supply in each country. Each country s information was consolidated in a regional report. All of the decision makers received an electronic copy of the regional consolidated report on a quarterly basis. The information has helped countries to improve medication supply on three levels. Countries have expedited the process to order medications, redistributed medications in the country and exchanged/donated medications between countries in the region. At the August, 2011 regional meeting to improve the supply of antimalarial medications in Lima, Peru, the participants agreed to strengthen and institutionalize the reporting process. The agreement included transferring the task of collection, analysis and distribution of the report to a regional organization. The Direccion Gestion de Medicamentos, Insumos y Drogas (DIDEMID) (Office for Management of Medications, Supplies and Drugs in English) in Peru offered to support the process. This document describes the procedure for the regional monitoring of the availability of medications. Description of the procedure for the collection and analysis of national and regional information 1. In the last week of each quarter (December, March, June and September) the director of the National Malaria Control Program, or designee, in each country requests the Warehouse Report (Annex 1) from all central and regional warehouses. Countries that already have a regular reporting system should begin this process at step four (4). 4

5 2. The central and department warehouses record the information on the electronic form Warehouse Report. Detailed instructions for completing this form are detailed in annex 1. The following items should be taken into consideration when completing the report. a. Annex 2 lists the medications needed for the report. The warehouse should mark 1 for medications that are required in the warehouse and a 0 for medications that are not required based on the Standard Treatment Guidelines. b. Do not include medications that are expired or in poor condition in the count. c. Average distribution is obtained by dividing total distribution over the previous 12 months by The distribution should only include distribution within the country and not include donations to other countries. 3. The central and department warehouses send the Warehouse Report to the director of the NMCP in the first five calendar days of the new quarter. (January, April, July and October) 4. In the first 10 calendar days of the new semester (January, April, July and October) the technical team from the NMCP consolidates the data from the central warehouse and regional warehouses in the form titled National_Consolidation (Annex 3). The completed form is sent to Dirección General de Medicamentos, Insumos y Drogas (DIGEMID) in Peru in electronic format. The address is listed in the footnote below In the first ten days of each new quarter (January, April, July and October) the technical team from the NMCP of each country analyzes the information and indicators and writes a national report which is disseminated to the central and department warehouse managers. There is an sample of the report in Annex Within the first 15 days of the quarter (January, April, July and October), DIGEMID consolidates and analyzes the information from each country that was received in electronic format in the report titled Regional_Consolidation (Annex 5). DIGEMID can clarify any discrepancies and unclear information during this time. 7. Within the first 20 calendar days of the new semester, DIGEMID in Peru writes a technical report highlighting the regional /distribution and supply situation. See Annex 6 for an example report. 1 Alternatively, if distribution information is not reliable, countries can use two alternatives to estimate average monthly. Either method is only useful if countries have accurate information. 1) The quantity of medications consumed by patients in the previous 12 months divided by 12; 2) Morbidity Method: The number of cases expected to be treated in the next year based on prior data multiplied by treatment scheme divided by DIGEMID, Calle Coronel Odrizola 111, San Isidro, Peru;, Attn: Thalia Chaquilla, Telephone: tchaqilla@digemid.minsa.gob.pe. 5

6 8. DIGEMID distributes the final report the last day of the first month of the new quarter (January, April, July and October). The report is sent to the authorities of the NMCP, cooperative technical agencies and other decision makers. 6

7 Indicators Severe and Special Case malaria treatments P. vivax treatments P. falciparum treatments Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no) s Average Monthly Distribution/Consumption according to Units to be received in the next semester Annex 1. Warehouse Report Regional Monitoring System for the Availability of Antimalarial Medications Warehouse Report Reporting warehouse/almacén que reporta: Quarter/Trimestre reportado (1, 2, 3 or 4): Report Date/Fecha de reporte: Responsible party/responsable : Telephone/Teléfono: /Correo electrónico: Name of Warehouse Medications/Medicamentos 001 Artemether-Lumefantrine 20/120 mg X 6 tablet 002 Artemether-Lumefantrine 20/120 mg X 12 tablet 003 Artemether-Lumefantrine 20/120 mg X 18 tablet 004 Artemether-Lumefantrine 20/120 mg X 24 tablet 005 Artesunate 50 mg tablet 006 Artesunate 100 mg tablet 007 Artesunate 250 mg tablet 008 Artesunate+ SP (Children) 009 Artesunate+ SP (Adolescent) 010 Artesunate+ SP (Adults) 011 Artesunate-Mefloquine 25/55 mg x 3 tablet. 012 Artesunate-Mefloquine 25/55 mg x 6 tablet. 013 Artesunate-Mefloquine 100/220 mg x 3 tablet. 014 Artesunate+Mefloquine 100/220 mg x 6 tablet. 015 Mefloquine 250 mg tablet 016 Sulfadoxine-Pyrimethamine 25/500mg tablet 017 Chloroquine fosfato 150 mg tablet 018 Chloroquine fosfato 100 mg tablet 019 Primaquine fosfato 5 mg tablet 020 Primaquine fosfato 7.5 mg tablet 021 Primaquine fosfato 15 mg tablet 022 Artemether 80 mg/1 ml, 1 ml ampoules 023 Artesunate rectal 50 mg 024 Artesunate rectal 100 mg 025 Artesunate sodium bicarbonate 60 mg/1 ml ampoule 026 Clindamycin Hydrochloride 300 mg Capsule 027 Clindamycin Phosphate 150 mg/ ml x 4 ml injectable 028 Clindamycin Hydrochloride 150 mg Capsule 029 Clindamycin 75mg/5mL suspension 030 Doxycycline 100 mg Capsule 031 Quinine Hydrochloride 300 mg/ ml x 2 ml injectable 032 Quinine Hydrochloride 600 mg/ ml x 2 ml injectable 033 Quinine Dihydrochloride 125 mg/ ml x 4 ml injectable 034 Quinine Dihydrochloride 300 mg/ ml x 2 ml injectable 035 Quinine Dihydrochloride 600mg/ml x 2 ml injectable 036 Quinine Sulfate 300mg tablet 037 Quinine Sulfate 500 mg tablet Number of medications which are part of the Standard Treatment Guideline (STG) that are. 0 Number of medications required in the STG 0 % of STG medications #DIV/0! % of STG medications not #DIV/0! % of STG medications with availability less than the minimum security stock (3 months) #DIV/0! % of STG medications which are overstocked (more than 24 months of availability) #DIV/0! 7

8 Instructions: N CONCEPTO DESCRIPCIÓN 1 Reporting Warehouse: Put the name of the reporting warehouse 2 Quarter: Put the number of the semester that is being submitted 1 (Jan.- Mar.), 2 (Apr.-Jun.), 3 (Jul.- Sep.) or 4 (Oct.- Dec.) 3 Report Date: Put the date (day, month and year) the report is completed 4 Responsible Party: Put the name of the person that is completeing the report 5 Telephone and 6 Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no) Average monthly Units to be received in the next semester Put the telephone and the address of the warehouse that is reporting Put one (1) next to the medications that are obligatory based on the guidelines for the warehouse. Put zero (0) for medications which are not obligatory for the warehouse. Put the count of medications (in units) for all medications in the warehouse. If there are medicaions that are un but should be in the warehouse, put zero (0). Put the average distribution or the data. Complete only for the central warehouse. Put the amount of medications to be received in the warehouse in the semester that follows the report. 8

9 Severe and Special Case malaria treatments P. vivax treatments P. falciparum treatments Annex 2: List of Antimalarial Medications 001 Artemether-Lumefantrine 20/120 mg X 6 tablet 002 Artemether-Lumefantrine 20/120 mg X 12 tablet 003 Artemether-Lumefantrine 20/120 mg X 18 tablet 004 Artemether-Lumefantrine 20/120 mg X 24 tablet 005 Artesunate 50 mg tablet 006 Artesunate 100 mg tablet 007 Artesunate 250 mg tablet 008 Artesunate+ SP (Children) 009 Artesunate+ SP (Adolescent) 010 Artesunate+ SP (Adults) 011 Artesunate-Mefloquine 25/55 mg x 3 tablet. 012 Artesunate-Mefloquine 25/55 mg x 6 tablet. 013 Artesunate-Mefloquine 100/220 mg x 3 tablet. 014 Artesunate+Mefloquine 100/220 mg x 6 tablet. 015 Mefloquine 250 mg tablet 016 Sulfadoxine-Pyrimethamine 25/500mg tablet 017 Chloroquine Phosphate 150 mg tablet 018 Chloroquine Phosphate 100 mg tablet 019 Primaquine Phosphate 5 mg tablet 020 Primaquine Phosphate 7.5 mg tablet 021 Primaquine Phosphate 15 mg tablet 022 Artemether 80 mg/1 ml, 1 ml ampoules 023 Artesunate rectal 50 mg 024 Artesunate rectal 100 mg 025 Artesunate sodium bicarbonate 60 mg/1 ml ampoule 026 Clindamycin Hydrochloride 300 mg Capsule 027 Clindamycin Phosphate 150 mg/ ml x 4 ml injectable 028 Clindamycin Hydrochloride 150 mg Capsule 029 Clindamycin 75mg/5mL suspension 030 Doxycycline 100 mg Capsule 031 Quinine Hydrochloride 300 mg/ ml x 2 ml injectable 032 Quinine Hydrochloride 600 mg/ ml x 2 ml injectable 033 Quinine Dihydrochloride 125 mg/ ml x 4 ml injectable 034 Quinine Dihydrochloride 300 mg/ ml x 2 ml injectable 035 Quinine Dihydrochloride 600mg/ml x 2 ml injectable 036 Quinine Sulfate 300mg tablet 037 Quinine Sulfate 500 mg tablet 9

10 Indicators Severe and Special Case malaria treatments P. vivax treatments P. falciparum treatments Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no) s Average Monthly Distribution/Consumption Units to be received in the next semester s Average Monthly Distribution/Consumption No of warehouses with no availability Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no) s Average Monthly Distribution/Consumption Anex 3: Consolidated National Report Reporting country/ País que reporta: Quarter/Trimestre reportado (1, 2, 3 or 4): Report Date/ Fecha de reporte: Regional Monitoring System for the Availability of Antimalarial Medications Consolidated National Report Responsible party/responsible : Telephone/Teléfono: /Correo electrónico: No. of departments that reported this quarter No. of departments that should report % of departments that reported availability #DIV/0! Central Warehouse/Almacén Central Consolidated Depart. Warehouses/Almacenes Depart One Medications/Medicamentos 001 Artemether-Lumefantrine 20/120 mg X 6 tablet 002 Artemether-Lumefantrine 20/120 mg X 12 tablet 003 Artemether-Lumefantrine 20/120 mg X 18 tablet 004 Artemether-Lumefantrine 20/120 mg X 24 tablet 005 Artesunate 50 mg tablet 006 Artesunate 100 mg tablet 007 Artesunate 250 mg tablet 008 Artesunate+ SP (Children) 009 Artesunate+ SP (Adolescent) 010 Artesunate+ SP (Adults) 011 Artesunate-Mefloquine 25/55 mg x 3 tablet. 012 Artesunate-Mefloquine 25/55 mg x 6 tablet. 013 Artesunate-Mefloquine 100/220 mg x 3 tablet. 014 Artesunate+Mefloquine 100/220 mg x 6 tablet. 015 Mefloquine 250 mg tablet 016 Sulfadoxine-Pyrimethamine 25/500mg tablet 017 Chloroquine phosphate 150 mg tablet 018 Chloroquine phosphate 100 mg tablet 019 Primaquine phosphate 5 mg tablet 020 Primaquine phosphate 7.5 mg tablet 021 Primaquine phosphate 15 mg tablet 022 Artemether 80 mg/1 ml, 1 ml ampoules 023 Artesunate rectal 50 mg 024 Artesunate rectal 100 mg 025 Artesunate sodium bicarbonate 60 mg/1 ml ampoule 026 Clindamycin Hydrochloride 300 mg Capsule 027 Clindamycin Phosphate 150 mg/ ml x 4 ml injectable 028 Clindamycin Hydrochloride 150 mg Capsule 029 Clindamycin 75mg/5mL suspension 030 Doxycycline 100 mg Capsule 031 Quinine Hydrochloride 300 mg/ ml x 2 ml injectable 032 Quinine Hydrochloride 600 mg/ ml x 2 ml injectable 033 Quinine Dihydrochloride 125 mg/ ml x 4 ml injectable 034 Quinine Dihydrochloride 300 mg/ ml x 2 ml injectable 035 Quinine Dihydrochloride 600mg/ml x 2 ml injectable 036 Quinine Sulfate 300mg tablet 037 Quinine Sulfate 500 mg tablet No. of department warehouses that report medication availability data Number of medications which are part of the Standard Treatment Guideline (STG) that are. Number of medications required in the STG % of STG medications #DIV/0! #DIV/0! #DIV/0! % of STG medications not #DIV/0! #DIV/0! #DIV/0! % of STG medications with availability less than the minimum security stock (3 months) #DIV/0! #DIV/0! #DIV/0! % of STG medications which are overstocked (more than 24 months of availability) #DIV/0! #DIV/0! #DIV/0! 10

11 Instructions N CONCEPTO DESCRIPCIÓN 1 Reporting Country Put the name of the country 2 Quarter: Put the number of the semester that is being submitted, ie. 1 (Jan.- Mar.), 2 (Apr.-Jun.), 3 (Jul.- Sep.) or 4 (Oct.- Dec.) 3 Report Date: Put the date (day, month and year) the report is completed 4 Responsible Party: Put the name of the person that is completeing the report 5 Telephone and Put the telephone and the address of the warehouse that is reporting 6 Central Warehouse Copy the information from the warehouse reports 6.1. Obligatory medication based on the standard treatment Guidelines (1=Yes, 0=No) Medicamento Obligatorio de acuerdo a la norma nacional Put one (1) next to the medications that are obligatory based on the guidelines for the warehouse. Put zero (0) for medications which are not obligatory for the warehouse. 6.2 Put the count of medications (in units) for all medications in the warehouse. If there are medicaions that are un but should be in the warehouse, put zero (0) Average monthly Availability in months Put the average distribution or the data. This column calculates automatically. You do not need to do anything. 6.5 Units to be received in the next semester 7 Consolidated Regional Warehouses 8 One/two/Three/ Complete only for the central warehouse. Put the amount of medications to be received in the warehouse in the semester that follows the report. This column calculates automatically based on the information provided in the columns for each department warehouses. Copy the information from the reports from each department warehouse 8.1 Obligatory medication based on the standard treatment Guidelines (1=Yes, 0=No) Medicamento Obligatorio de acuerdo a la norma nacional Put one (1) next to the medications that are obligatory based on the guidelines for the warehouse. Put zero (0) for medications which are not obligatory for the warehouse. 8.2 Put the count of medications (in units) for all medications in the warehouse. If there are medicaions that are un but should be in the warehouse, put zero (0) Average monthly Availability in months Put the average distribution or the data. This column calculates automatically. You do not need to do anything. 11

12 Indicators Severe and Special Case malaria treatments P. vivax treatments P. falciparum treatments Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no) s Average Monthly Distribution/Consumption according to Units to be received in the next semester s Average Monthly Distribution/Consumption according to No of warehouses with no availability Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no) s Average Monthly Distribution/Consumption according to Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no) s Average Monthly Distribution/Consumption according to Annex 4. Technical Report for the national Situation for Antimalarial Availability Ecuador, 2011 (Model) Introduction: Why the data is collected Utility for decision making Findings: Number of warehouses that report Limitations in the analysis Availability, stock outs or overstocked situation classified by type of medication. (P. Vivax, P. Falcipirum, and treatment for special case and severe malaria) Table 1. Availability of antimalarials in the Central and department warehouses Central Warehouse/Almacén Central Consolidated Depart. Warehouses/Almacenes Depart One Two Medications/Medicamentos 001 Artemether-Lumefantrine 20/120 mg X 6 tablet Artemether-Lumefantrine 20/120 mg X 12 tablet Artemether-Lumefantrine 20/120 mg X 18 tablet Artemether-Lumefantrine 20/120 mg X 24 tablet Artesunate 50 mg tablet 1 7, Artesunate 100 mg tablet Artesunate 250 mg tablet Artesunate+ SP (Children) Artesunate+ SP (Adolescent) Artesunate+ SP (Adults) Artesunate-Mefloquine 25/55 mg x 3 tablet Artesunate-Mefloquine 25/55 mg x 6 tablet Artesunate-Mefloquine 100/220 mg x 3 tablet Artesunate+Mefloquine 100/220 mg x 6 tablet Mefloquine 250 mg tablet 1 16, Sulfadoxine-Pyrimethamine 25/500mg tablet Chloroquine phosphate 150 mg tablet 1 753,937 51, Chloroquine phosphate 100 mg tablet Primaquine phosphate 5 mg tablet 1 40,325 1, Primaquine phosphate 7.5 mg tablet Primaquine phosphate 15 mg tablet 1 235,097 6, Artemether 80 mg/1 ml, 1 ml ampoules Artesunate rectal 50 mg Artesunate rectal 100 mg Artesunate sodium bicarbonate 60 mg/1 ml ampoule Clindamycin Hydrochloride 300 mg Capsule 1 4, Clindamycin Phosphate 150 mg/ ml x 4 ml injectable Clindamycin Hydrochloride 150 mg Capsule 0 3, Clindamycin 75mg/5mL suspension Doxycycline 100 mg Capsule Quinine Hydrochloride 300 mg/ ml x 2 ml injectable Quinine Hydrochloride 600 mg/ ml x 2 ml injectable Quinine Dihydrochloride 125 mg/ ml x 4 ml injectab Quinine Dihydrochloride 300 mg/ ml x 2 ml injectab Quinine Dihydrochloride 600mg/ml x 2 ml injectable Quinine Sulfate 300mg tablet 1 11, Quinine Sulfate 500 mg tablet 0 No. of department warehouses that report medication availability data Number of medications which are part of the Standard Treatment Guideline (STG) that are. Number of medications required in the STG % of STG medications % of STG medications not % of STG medications with availability less than the minimum security stock (3 months) % of STG medications which are overstocked (more than 24 months of availability) 67% 100% 100% 100% 33% 0% 0% 0% 0% 8% 25% 0% 33% 42% 38% 42% 12

13 Indicadores Severe and Special Case malaria treatments P. vivax treatments P. falciparum treatments Annex 5: Consolidated Regional Report Quarter/Trimestre reportado (1, 2, 3 or 4): Report Date/ Fecha de reporte: Regional Monitoring System for the Availability of Antimalarial Medications Regional Report Responsible party/ Responsable: Telephone/ Teléfono: / Correo electrónico: Country 1 Country 2 Country 3 Central Department Central Department Central Department Medications/Medicamento 001 Artemether-Lumefantrine 20/120 mg X 6 tablet 002 Artemether-Lumefantrine 20/120 mg X 12 tablet 003 Artemether-Lumefantrine 20/120 mg X 18 tablet 004 Artemether-Lumefantrine 20/120 mg X 24 tablet 005 Artesunate 50 mg tablet 006 Artesunate 100 mg tablet 007 Artesunate 250 mg tablet 008 Artesunate+ SP (Children) 009 Artesunate+ SP (Adolescent) 010 Artesunate+ SP (Adults) 011 Artesunate-Mefloquine 25/55 mg x 3 tablet. 012 Artesunate-Mefloquine 25/55 mg x 6 tablet. 013 Artesunate-Mefloquine 100/220 mg x 3 tablet. 014 Artesunate+Mefloquine 100/220 mg x 6 tablet. 015 Mefloquine 250 mg tablet 016 Sulfadoxine-Pyrimethamine 25/500mg tablet 017 Chloroquine phosphate 150 mg tablet 018 Chloroquine phosphate 100 mg tablet 019 Primaquine phosphate 5 mg tablet 020 Primaquine phosphate 7.5 mg tablet 021 Primaquine phosphate 15 mg tablet 022 Artemether 80 mg/1 ml, 1 ml ampoules 023 Artesunate rectal 50 mg 024 Artesunate rectal 100 mg 025 Artesunate sodium bicarbonate 60 mg/1 ml ampoule 026 Clindamycin Hydrochloride 300 mg Capsule 027 Clindamycin Phosphate 150 mg/ ml x 4 ml injectable 028 Clindamycin Hydrochloride 150 mg Capsule 029 Clindamycin 75mg/5mL suspension 030 Doxycycline 100 mg Capsule 031 Quinine Hydrochloride 300 mg/ ml x 2 ml injectable 032 Quinine Hydrochloride 600 mg/ ml x 2 ml injectable 033 Quinine Dihydrochloride 125 mg/ ml x 4 ml injectable 034 Quinine Dihydrochloride 300 mg/ ml x 2 ml injectable 035 Quinine Dihydrochloride 600mg/ml x 2 ml injectable 036 Quinine Sulfate 300mg tablet 037 Quinine Sulfate 500 mg tablet Número de almacenes departamentales que reportan datos de disponibilidad de medicamentos Número de medicamentos que son parte de la norma nacional que están disponibles Número de medicamentos requeridos por la norma nacional % de medicamentos en la norma nacional disponibles % de medicamentos en la norma nacional no disponibles % de medicamentos que son parte de la norma nacional con una disponibilidad menor al stock de seguridad (menos de 3 meses) % de medicamentos que son parte de la norma nacional que están sobre abastecidos (mas de 24 meses) 13

14 Instructions N CONCEPTO DESCRIPCIÓN 1 Quarter: Put the number of the semester that is being submitted, ie. 1 (Jan.-Mar.), 2 (Apr.-Jun.), 3 (Jul.- Sep.) or 4 (Oct.- Dec.) 2 Report Date: Put the date (day, month and year) the report is completed 3 Responsible Party: Put the name of the person that is completeing the report 4 Telephone and 5 Country 1, Country 2, Country 3, Country 1: Central 5.1 Put the telephone and the address of the warehouse that is reporting Put the name of the country that is completing the report and copy the data from their national Reports Copy the quantity ( in units) of each medication in the central warehouse for each country. This information can be found in the Consolidated National Report from each country. Put a zero for any medications that are stocked out. 5.2 Months of Availability Country 1: Department Months of Availability Copy the in the central warehouse. This information is obtained in the Consolidated national report of each country. Use two decimils for this information. Copy the quantity ( in units) of each medication in the regional warehouses for each country. This information can be found in the Consolidated National Report from each country. The report should only include the data ffrom the consolidated regional column. Put a zero for any medications that are stocked out. Copy the in the regional warehouse. This information is obtained in the Consolidated national report of each country. The report should only include the consolidated warehouse information. Use two decimils for this information. 14

15 Severe and Special Case malaria treatments P. vivax treatments P. falciparum treatments Annex 6: Quarterly Technical Report on the Regional Situation of Antimalarial Availability. 2 nd Quarter 2011 (Model) Introduction Rationale for collecting the data on a regional and national level Countries and agencies that are participating Utility for decision making Findings Number of warehouses that are reporting data Limitations in the analysis Availability, stock out or overstock situations classified by type of medication. (P. vivax, P. falcipirum, or treatments for severe or special case malaria) Table 1: Availability of antimalarials en central and department warehouses Country/ País Number of medications that are part of the national STG s. % of medications, 2 nd quarter 2011 Central Level % of medications, 3rd quarter, 2011 Department Level % of medications, 2 nd quarter 2011 % of medications, 3rd quarter, 2011 Bolivia 12 66% 66% 100% 100% Brasil 18 89% 94% nd nd Colombia 13 92% 54% 91% 69% Ecuador 9 89% 67% 100% 100% Perú 8 38% 13% 100% 100% Annex1: Country 1 Country 2 Country 3 Central Department Central Department Central Department Medications/Medicamento 001 Artemether-Lumefantrine 20/120 mg X 6 tablet 2, , , Artemether-Lumefantrine 20/120 mg X 12 tablet 7, , , Artemether-Lumefantrine 20/120 mg X 18 tablet 7, , , Artemether-Lumefantrine 20/120 mg X 24 tablet 50, , , Artesunate 50 mg tablet 7, , Artesunate 100 mg tablet 007 Artesunate 250 mg tablet 008 Artesunate+ SP (Children) 009 Artesunate+ SP (Adolescent) 010 Artesunate+ SP (Adults) 011 Artesunate-Mefloquine 25/55 mg x 3 tablet , Artesunate-Mefloquine 25/55 mg x 6 tablet , Artesunate-Mefloquine 100/220 mg x 3 tablet , Artesunate+Mefloquine 100/220 mg x 6 tablet , Mefloquine 250 mg tablet 16, , Sulfadoxine-Pyrimethamine 25/500mg tablet 017 Chloroquine phosphate 150 mg tablet 223, , ,024, , , Chloroquine phosphate 100 mg tablet 019 Primaquine phosphate 5 mg tablet 34, , ,376, , Primaquine phosphate 7.5 mg tablet 021 Primaquine phosphate 15 mg tablet 183, , ,042, , , Artemether 80 mg/1 ml, 1 ml ampoules Artesunate rectal 50 mg 7, , Artesunate rectal 100 mg 16, , Artesunate sodium bicarbonate 60 mg/1 ml ampoule 4, ,220 1, , Clindamycin Hydrochloride 300 mg Capsule 47, Clindamycin Phosphate 150 mg/ ml x 4 ml injectable 3, Clindamycin Hydrochloride 150 mg Capsule Clindamycin 75mg/5mL suspension 030 Doxycycline 100 mg Capsule 75, Quinine Hydrochloride 300 mg/ ml x 2 ml injectable 032 Quinine Hydrochloride 600 mg/ ml x 2 ml injectable Quinine Dihydrochloride 125 mg/ ml x 4 ml injectable , , Quinine Dihydrochloride 300 mg/ ml x 2 ml injectable 11, ,220 2, , , Quinine Dihydrochloride 600mg/ml x 2 ml injectable 036 Quinine Sulfate 300mg tablet 037 Quinine Sulfate 500 mg tablet 243,

16 Annex 2 Indicators Bolivia Brazil Colombia Ecuador Perú Central Departament Central Central Departament Central Departament Central Departament Number of department warehouses that report data for availability of medications Number of national standard treatment guideline medications Number of medications required by the national standard treatment guidelines % of standard treatment guideline medications % of standard treatment guideline medications not % of national standard treatment guideline medications with availability less than the minimum security stock (less than 3months) % of national standard treatment guideline medications over stocked (more than 24 months) % 100% 94% 54% 77% 67% 100% 13% 100% 33% 0% 6% 46% 23% 33% 0% 88% 0% 8% 0% 22% 15% 62% 11% 0% 13% 13% 25% 50% 17% 8% 0% 44% 67% 0% 25% 16